ETCTN Trials by Disease/Treatment Area: Gynecologic Cancer

**Cervical/vaginal**

- **10132**: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers

- **9592**: Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer

**Endometrial**

- **10104**: A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer (Exploratory cohort eligibility: Endometrial carcinosarcoma only)

- **10017**: A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer

**Ovarian**

- **9948**: Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

- **10150**: A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

- **▼ 9676**: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

**Uterine sarcoma**

- **10250**: A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

**NOTE**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 20, 2019